by Alicia Gailliez, Business Development Manager, One Nucleus
The One Nucleus Boston Bootcamp 2026 once again brought together an ambitious cohort of UK life science innovators to immerse themselves in one of the world’s most dynamic biotech ecosystems. The selected winning companies this year were ExpressionEdits, Monument Therapeutics, Profionics and Stick Therapeutics. Joining the winners were those self-funding their participation including Luvida, RNera Bio and Quaisr.
Across three days of expert discussions, networking opportunities, pitching opportunities and peer exchange, there was one message that stood out clearly: Boston is an impressive ecosystem that remains full of opportunity for accessing a clear route to scale, but success requires the right support network, clarity of how you stand-out and careful preparation to show how you are positioned to progress to the next key value inflection point.
As with all the Bootcamp cohorts, and no different this year, participating companies have a range of motivations for participating, whether that is seeking collaborations, fundraising, clinical development or establishing a fractional, on the ground presence. Success depends on engaging the right advisors in each area, a process the Boston Bootcamp helps participants navigate. Companies benefit from early engagement with advisors who understand both the UK and US systems.
What follows highlights the main themes to emerge, offering a teaser ahead of ON Helix 2026 on 9 July, where the key takeaways will be discussed in greater depth.
Key Takeaways from the Boston Bootcamp 2026
Capital efficient opportunities
Compared with last year’s Bootcamp, sentiments on the ground felt more optimistic. It was encouraging to hear that US market conditions were beginning to move again, leading to increased capital deployment that was translating into hiring activity and company growth.
It was also encouraging to hear that investor syndicates were showing greater flexibility with a US presence not always viewed as an essential pre-requisite for investment.
One notable takeaway was the contrast in market cadence. The US ecosystem operates with greater urgency, with investors and companies often moving more quickly and showing a higher tolerance for risk.
Finally, the significant vacancy rate across parts of the market were positioned as an opportunity for companies looking to establish or expand a presence in MA.
The UK must continue to sharpen its value proposition to the US
A key reflection from last year’s Bootcamp was a need for the UK life sciences sector to do more to articulate the unique strengths it brings to the Boston ecosystem. While the Massachusetts ecosystem really does dwarf that of the UK, this year’s Bootcamp highlighted a strong appetite to growth and innovation coming in from outside. The UK, therefore, must be bolder in communicating its value proposition, especially as the US is increasingly looking to China rather than Europe as the major external source of innovation.
The third day of the Bootcamp programme showcased the breadth and quality of the UK drug discovery capabilities and research ecosystems, providing the Boston-based participants with valuable insight into both the scientific strengths already established in the UK and the emerging areas of innovation that continue to grow. Representing and championing UK excellence during the showcase were the Milner Therapeutics Institute, Domainex, Advanced Research Clusters, Babraham Research Campus and Metrion Biosciences.
Speed is King
Regulation and the evolving role of the FDA featured prominently in the programme. There were encouraging perspectives around the FDA being open to external US generated clinical data, but caution over areas like cell and gene therapies. There was also recognition of the pressure that companies face to generate robust data quickly which remains intense. For many UK biotechs, balancing the speed expected by US investors against their available runway continues to be a major challenge.
Innovation and partnering is becoming increasingly global
The Bootcamp helped to emphasise the fact that innovation depends on how quickly businesses can move across borders and connect with investors, regulators, partners and customers in different markets. It demonstrated the clear role of international connectors such as MassBio and the British Consulate General Boston in providing this innovation infrastructure, helping ambitious companies navigate complexity and reduce any friction in moving between borders. In today's life sciences sector, success is no longer determined solely by the strength of the local ecosystem a company is based in, but its ability to operate globally, accessing talent, capital, expertise, patient populations and commercial opportunities wherever they exist.
Unexpected insights
Attendees also derived value from some of the more unexpected practical learnings that emerged during the programme. Sessions exploring topics such as waiver of privilege, handling sensitive information during diligence, and even the use of AI tools highlighted the importance of governance in cross-border transactions and engagement. Sometimes, the differences between US and UK law are relatively subtle, but if misunderstood can still have major consequences for a business.
The Bootcamp creates value through its own network
Beyond the formal sessions, many participants reflected on the value of the peer network itself. The Bootcamp not only connected UK innovators with Boston expertise, but also strengthened relationships across the UK cohort, creating new opportunities for collaboration and shared learning, whilst also creating friendships.
ON Helix 2026
ON Helix on 9 July will reunite Bootcamp participants to share insights from the key topics discussed in Boston with the wider network. In an era where competitive advantage increasingly belongs to biotechs who can operate ‘fluently’ across different geographies, this is a discussion not to be missed!
With thanks to the generosity of our sponsors and hosts out in Boston. Thank you to Tunnell Consulting, Inc., Wolf Greenfield, Taylor Wessing, Mewburn Ellis, RSM UK, RSM US LLP, Talentmark, Knight Frank, BioMed Realty, MassBio, Life Science Nation, Gunderson Dettmer, Breakthrough Properties, Orrick & Associates, LLP, Cresa and the British Consulate-General Boston.